Additionally, in a phase I/II clinical trial (KCT0000831) performed by Baek et al., moDCs were pulsed with autologous whole tumor lysate and keyhole limpet hemocyanin (KLH) and combined with IL-2 treatment in 10 OC patients. This evidence concerns the gene IL2 and neoplasm.